# Beijing Hotgen Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-hotgen-biotech-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.hotgen.com.cn
- Latest round: Series A (Jan 11, 2019)
- Investors on record: 2

## About

Based in Beijing, China and established in 2005, Beijing Hotgen Biotech Co., Ltd. is a provider of clinical POCT and biosafety testing equipment. It has acquired High-Tech Enterprise Certificate and others. In January 2019, Beijing Hotgen Biotech Co., Ltd. closed a series A funding from new investor Shenzhen GTJA Investment Group. In September 2019, it was listed on the Shanghai Stock Exchange.

The company's products include in vitro diagnostic reagents and supporting instruments, hepatitis B virus large protein (HBV-LP) assay kits, Vibrio cholerae O1 group detection kits, etc. The products are used in military biological counter-terrorism, customs inspection and quarantine, CDC on-site testing, pesticide and veterinary drug residue testing and other fields.

The company generates revenue by developing in-vitro diagnostic (IVD), point-of-care-testing (POCT) and biodefense products.

## Funding rounds

- Series A, Jan 11, 2019 — GTJA Investment Group
- Angel, May 22, 2014 — Fortune Capital

## Investors

- Fortune Capital — Angel
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series A